Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy

Translational Research

Volumn 155, Issue 1, 2010, Pages 20-26

  Kasama, Tsuyoshi ^a   Wakabayashi, Kuninobu ^a   Sato, Michihito ^a   Takahashi, Ryo ^a   Isozaki, Takeo ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; D DIMER; EOTAXIN 3; FIBRIN; FRACTALKINE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR;

AORTA ARCH SYNDROME; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CHURG STRAUSS SYNDROME; DENDRITIC CELL; ENDOTHELIUM; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FIBROSING ALVEOLITIS; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; HUMAN; IMMUNOREGULATION; ISCHEMIC COLITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MICROSCOPIC POLYANGIITIS; NATURAL KILLER CELL; NERVE CELL; NONHUMAN; PATHOGENESIS; PERICARDITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEURISY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TEMPORAL ARTERITIS; VASCULAR DISEASE; VASCULITIS;

EID: 71049130765     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.08.009     Document Type: Review

References (65)

1. Buckley C.D., Rainger G.E., Nash G.B., and Raza K. Endothelial cells, fibroblasts and vasculitis. Rheumatology 44 (2005) 860-863
2. Kaneider N.C., Leger A.J., and Kuliopulos A. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J 273 (2006) 4416-4424
3. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
4. Kunkel S.L., Lukacs N., Kasama T., and Strieter R.M. The role of chemokines in inflammatory joint disease. J Leukoc Biol 59 (1996) 6-12
5. Baggiolini M. Chemokines and leukocyte traffic. Nature 392 (1998) 565-568
6. Moser B., Wolf M., Walz A., and Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25 (2004) 75-84
7. Mantovani A., and Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 10 (1989) 370-375
8. Sneller M.C., and Fauci A.S. Pathogenesis of vasculitis syndromes. Med Clin North Am 81 (1997) 221-242
9. Cid M.C., Segarra M., Garcia-Martinez A., and Hernandez-Rodriguez J. Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Curr Rheumatol Rep 6 (2004) 184-194
10. Bacon P.A. Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects. Curr Opin Rheumatol 17 (2005) 49-55
11. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 95 (2004) 858-866
12. Cid M.C., and Vilardell C. Tissue targeting and disease patterns in systemic vasculitis. Best Pract Res Clin Rheumatol 15 (2001) 259-279
13. Polzer K., Karonitsch T., Neumann T., et al. Eotaxin-3 is involved in Churg-Strauss syndrome-a serum marker closely correlating with disease activity. Rheumatology 47 (2008) 804-808
14. Ellingsen T., Elling P., Olson A., et al. Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica. Ann Rheum Dis 59 (2000) 775-780
15. Bruhl H., Vielhauer V., Weiss M., Mack M., Schlondorff D., and Segerer S. Expression of DARC, CXCR3 and CCR5 in giant cell arteritis. Rheumatology 44 (2005) 309-313
16. Krupa W.M., Dewan M., Jeon M.S., et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 161 (2002) 1815-1823
17. Ma-Krupa W., Jeon M.S., Spoerl S., Tedder T.F., Goronzy J.J., and Weyand C.M. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199 (2004) 173-183
18. Cid M.C., Hoffman M.P., Hernandez-Rodriguez J., et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology 45 (2006) 1356-1363
19. Lamprecht P., Bruhl H., Erdmann A., et al. Differences in CCR5 expression on peripheral blood CD4 + CD28- T-cells and in granulomatous lesions between localized and generalized Wegener's granulomatosis. Clin Immunol 108 (2003) 1-7
20. Bazan J.F., Bacon K.B., Hardiman G., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
21. Pan Y., Lloyd C., Zhou H., et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387 (1997) 611-617
22. Stievano L., Piovan E., and Amadori A. C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol 24 (2004) 205-228
23. Imai T., Hieshima K., Haskell C., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (1997) 521-530
24. Umehara H., Bloom E., Okazaki T., Domae N., and Imai T. Fractalkine and vascular injury. Trends Immunol 22 (2001) 602-607
25. Umehara H., Bloom E.T., Okazaki T., Nagano Y., Yoshie O., and Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 24 (2004) 34-40
26. Chen S., Bacon K.B., Li L., et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 188 (1998) 193-198
27. Ruth J.H., Volin M.V., Haines III G.K., et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 44 (2001) 1568-1581
28. Blaschke S., Koziolek M., Schwarz A., et al. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol 30 (2003) 1918-1927
29. Hasegawa M., Sato S., Echigo T., Hamaguchi Y., Yasui M., and Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 64 (2005) 21-28
30. Yajima N., Kasama T., Isozaki T., et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 52 (2005) 1670-1675
31. Fraticelli P., Sironi M., Bianchi G., et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107 (2001) 1173-1181
32. Matsunawa M., Odai T., Wakabayashi K., et al. Elevated serum levels of soluble CX3CL1 in patients with microscopic polyangiitis. Clin Exp Rheumatol 27 (2009) 72-78
33. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (1994) 187-192
34. Bjerkeli V., Damas J.K., Fevang B., Holter J.C., Aukrust P., and Froland S.S. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis possible role in vascular inflammation. Rheumatology 46 (2007) 1422-1427
35. Hergesell O., Andrassy K., and Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 75 (1996) 892-898
36. Matsunawa M., Isozaki T., Odai T., et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 54 (2006) 3408-3416
37. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
38. Kuryliszyn-Moskal A., Bernacka K., and Klimiuk P.A. Circulating intercellular adhesion molecule 1 in rheumatoid arthritis-relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clin Rheumatol 15 (1996) 367-373
39. Blann A.D., Herrick A., and Jayson M.I. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 34 (1995) 814-819
40. Boehme M.W., Schmitt W.H., Youinou P., Stremmel W.R., and Gross W.L. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 101 (1996) 387-394
41. Fong A.M., Robinson L.A., Steeber D.A., et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188 (1998) 1413-1419
42. Ahn S.Y., Cho C.H., Park K.G., et al. Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 164 (2004) 1663-1672
43. Kuryliszyn-Moskal A. Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities. Clin Rheumatol 17 (1998) 489-495
44. Feldmann M., and Pusey C.D. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 17 (2006) 1243-1252
45. Chapman G.A., Moores K.E., Gohil J., et al. The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol 392 (2000) 189-195
46. Furuichi K., Wada T., Iwata Y., et al. Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron 87 (2001) 314-320
47. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165 (2002) 1419-1425
48. Csernok E., Trabandt A., Muller A., et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42 (1999) 742-750
49. Lamprecht P., Kumanovics G., Mueller A., et al. Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy. Clin Exp Immunol 128 (2002) 181-186
50. Foussat A., Coulomb-L'Hermine A., Gosling J., et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 30 (2000) 87-97
51. Ruth J.H., Rottman J.B., Katschke Jr. K.J., et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 44 (2001) 2750-2760
52. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
53. O'Donnell C.J., and Levy D. Weighing the evidence for infection as a risk factor for coronary heart disease. Curr Cardiol Rep 2 (2000) 280-287
54. Mach F. The role of chemokines in atherosclerosis. Curr Atheroscler Rep 3 (2001) 243-251
55. Greaves D.R., Hakkinen T., Lucas A.D., et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 21 (2001) 923-929
56. Patel A., Jagadesham V.P., Porter K.E., Scott D.J., and Carding S.R. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 36 (2008) 20-27
57. Lucas A.D., Bursill C., Guzik T.J., Sadowski J., Channon K.M., and Greaves D.R. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108 (2003) 2498-2504
58. Combadiere C., Potteaux S., Gao J.L., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 (2003) 1009-1016
59. Damas J.K., Boullier A., Waehre T., et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 25 (2005) 2567-2572
60. McDermott D.H., Halcox J.P., Schenke W.H., et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 89 (2001) 401-407
61. Faure S., Meyer L., Costagliola D., et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287 (2000) 2274-2277
62. McDermott D.H., Fong A.M., Yang Q., et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 111 (2003) 1241-1250
63. Cook D.N., Chen S.C., Sullivan L.M., et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 21 (2001) 3159-3165
64. Muhlestein J.B., Anderson J.L., Hammond E.H., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97 (1998) 633-636
65. Nadareishvili Z.G., Koziol D.E., Szekely B., et al. Increased CD8(+) T cells associated with Chlamydia pneumoniae in symptomatic carotid plaque. Stroke 32 (2001) 1966-1972